Immunogenicity and Safety of Adjuvant and Adjuvant-Free Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age

Trial Profile

Immunogenicity and Safety of Adjuvant and Adjuvant-Free Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Hib-meningococcal vaccine groups A and C conjugate (Primary)
  • Indications Haemophilus infections; Meningococcal group A infections; Meningococcal group C infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Beijing Zhifei Lvzhu Biopharmaceutical
  • Most Recent Events

    • 06 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top